Acer Therapeutics Inc. (NASDAQ:ACER) announced its quarterly earnings results on Monday. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, Bloomberg Earnings reports.

Shares of Acer Therapeutics (ACER) opened at $17.89 on Tuesday. Acer Therapeutics has a fifty-two week low of $5.18 and a fifty-two week high of $22.63.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at

Separately, ValuEngine lowered shares of Acer Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 2nd.

Acer Therapeutics Company Profile

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Earnings History for Acer Therapeutics (NASDAQ:ACER)

Receive News & Ratings for Acer Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics Inc. and related companies with's FREE daily email newsletter.